AMLX Amylyx Pharmaceuticals Inc: Accounting Value per Share

Amylyx Pharmaceuticals (AMLX) - corporate logo

High development costs and strict FDA oversight create significant barriers to entry for new players in ALS therapy. This chart illustrates the price action of Amylyx Pharmaceuticals (AMLX), whose expert staff is driven by grants and the goal of curing patients. The indicator stands at 2.17. The business is currently seeking to reduce its dependence on a single drug by adapting its molecules for other pathologies.

Amylyx Pharmaceuticals Inc (AMLX) Equity per Share: for the period 07/04/2022 - 10/27/2026

amylyx.com - analytical breakdowns and key metrics (AMLX)

- price and consensus price forecast:
Price Chart Amylyx|AMLX - Price Target Chart
- market capitalization data:
Market Valuation Amylyx Pharmaceuticals, Inc.|AMLX - Business Value
- book capitalization data:
Net Assets per Single Share Amylyx Pharmaceuticals|AMLX - Accounting Capitalization|Market Capitalization to Book Value Ratio amylyx.com|AMLX - Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio Amylyx Pharmaceuticals|AMLX - Long-Term Debt to Capital|Short-Term Debt to Equity Amylyx Pharmaceuticals, Inc.|AMLX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Amylyx Pharmaceuticals, Inc.
Fundamental company valuation:Amylyx, AMLX
Manufactured products of Amylyx Pharmaceuticals, Inc.

Capital allows for the separation of the real value of assets from speculative market expectations. For Amylyx Pharmaceuticals (AMLX), this is critical when restructuring the portfolio following failures in late-stage trials. Net book value per share is calculated as the difference between all assets and liabilities, divided by the number of shares. The trend in this net book value per share reflects the company's actual asset foundation. The stability of this metric confirms solvency during the development of new molecules.

Competitors of Amylyx Pharmaceuticals (AMLX)

BIIB - Net Assets per Single Share|Neurocrine Corp (NBIX) - Net Assets per Single Share|Accounting Value per Share Regencell Bioscience|AXSM (axsome.com) - Equity per Share|Net Assets per Single Share ACADIA Pharmaceuticals Inc. (ACAD)|Equity per Share Xenon Pharmaceuticals Inc.|Viking Pharma - Book Value per Share|Net Asset Value per Share Supernus Corp SUPN|Accounting Value per Share CPRX (Catalyst Pharmaceuticals)|denalitherapeutics.com - Book Value per Share|Net Assets per Single Share Harmony Biosciences Holdings, Inc. (HRMY)|BHVN: Accounting Value of a Share|Net Assets per Single Share TRVI|Praxis Corp (PRAX) - Net Asset Value per Share|AVXL (Anavex Life Sciences) - Book Value per Share|Book Value per Share CBLL|Net Assets per Single Share PRTA (Prothena Biosciences)|Accounting Value per Share alector.com ALEC|ANNX: Accounting Value per Share|Omeros Corp - Net Asset Value per Share|NGNE - Net Assets per Single Share|acimmune.com (ACIU) - Net Assets per Single Share|Accounting Value per Share VYGR|Net Asset Value per Share Neumora|Accounting Value per Share Scilex Holding Co. (SCLX)|Equity per Share Tevogen Bio Inc. (TVGN)|Alpha Cognition (ACOG) - Accounting Value per Share|Accounting Value of a Share CGTX (Cognition Therapeutics Inc.)|Inhibikase Therapeutics, Inc. (IKT) - Net Assets per Single Share|Share Book Value Cassava Sciences Inc SAVA|Book Value per Share Assertio Therapeutics (ASRT)|COYA - Accounting Value of a Share|VTGN: Book Value per Share|OVID (Ovid Therapeutics) - Book Value per Share|ABOS - Net Assets per Single Share|Accounting Value of a Share CRVO|Net Assets per Single Share ATHE (Alterity Therapeutics)|Accounting Value per Share clene.com (CLNN)|Book Value per Share PEPG (PepGen)|Book Value per Share Jupiter Neurosciences, Inc. JUNS|RLMD: Book Value per Share|ANVS - Accounting Value per Share|Book Value per Share GRCE|Net Asset Value per Share Firefly Neuro|KLTO (ANEW Medical) - Accounting Value per Share|Book Value per Share NeuroSense Therapeutics, Ltd. (NRSN)|Accounting Value per Share Reviva Pharmaceuticals Holdings, Inc.|Book Price of a Share metaviatx.com (MTVA)|Book Value per Share NRXS|Net Assets per Share Helius Medical Technologies, Inc. HSDT|PASG: Book Value per Share|NEUP - Accounting Value per Share|NERV: Book Value per Share|ATHA (Athira Pharma Inc) - Book Value per Share|Net Assets per Single Share Addex Therapeutics, Ltd.|Net Assets per Single Share ALZN|CYCN (Cyclerion Therapeutics) - Net Assets per Single Share|Net Assets per Share protagenic.com (PTIX)|Book Value per Share KTTA (Pasithea Therapeutics Corp.)|Cortigent Inc - Book Value per Share|ATXI: Net Assets per Single Share|BCLI: Accounting Value per Share|Cara Therapeutics, Inc. (CARA) - Net Assets per Single Share|Net Assets per Single Share chromocell.com|Accounting Value per Share Eliem Therapeutics, Inc. (ELYM)|Equity per Share ITCI|Net Assets per Single Share Longboard Pharma LBPH|Equity per Share Marinus Pharma (MRNS)|NKGN: Book Value per Share|NRBO - Net Asset Value per Share|Sage Therapeutics - Accounting Value per Share|SNPX: Book Value per Share|Net Assets per Single Share Trevena, Inc TRVN|VIGL (Vigil Neuroscience, Inc.) - Accounting Value of a Share|Net Assets per Single Share WENA (Anew Medical)|Net Asset Value per Share cerevel.com